Euro Bond Sale Might Change The Case For Investing In Viatris (VTRS)

Simply Wall St.06-16

Viatris Inc. recently completed a euro-denominated fixed-income offering, issuing €648.30 million of 4.250% senior unsecured notes due June 17, 2033, at 99.739% of face value with attached guarantees ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2643788173?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-06-16 01:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2643788173","market":"hk","top_or_hot":-1,"title":"Euro Bond Sale Might Change The Case For Investing In Viatris (VTRS)","media":"Simply Wall St.","content":"<div>\n<p>Viatris Inc. recently completed a euro-denominated fixed-income offering, issuing €648.30 million of 4.250% senior unsecured notes due June 17, 2033, at 99.739% of face value with attached guarantees ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vtrs/viatris/news/euro-bond-sale-might-change-the-case-for-investing-in-viatri\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Euro Bond Sale Might Change The Case For Investing In Viatris (VTRS)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEuro Bond Sale Might Change The Case For Investing In Viatris (VTRS)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-16 01:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vtrs/viatris/news/euro-bond-sale-might-change-the-case-for-investing-in-viatri><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Viatris Inc. recently completed a euro-denominated fixed-income offering, issuing €648.30 million of 4.250% senior unsecured notes due June 17, 2033, at 99.739% of face value with attached guarantees ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vtrs/viatris/news/euro-bond-sale-might-change-the-case-for-investing-in-viatri\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vtrs/viatris/news/euro-bond-sale-might-change-the-case-for-investing-in-viatri","article_id":"2643788173","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vtrs/viatris/news/euro-bond-sale-might-change-the-case-for-investing-in-viatri","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2643788173","pubTimestamp":1781543701,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Viatris Inc. recently completed a euro-denominated fixed-income offering, issuing €648.30 million of 4.250% senior unsecured notes due June 17, 2033, at 99.739% of face value with attached guarantees and call features.\nThis move adds euro currency debt to Viatris’ capital structure, raising questions about how the new funding mix may influence its balance sheet flexibility and future capital allocation.\nWe’ll now examine how this new euro-denominated bond issuance, and the added euro debt on...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4583":"猴痘概念","VTRS":"Viatris Inc.","BK4007":"制药","TLT":"20+年以上美国国债ETF-iShares","AIPO":"Defiance AI and Power Infrastructure ETF","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","FXE":"欧元做多ETF-CurrencyShares","TLTW":"iShares 20+ Year Treasury Bond Buywrite Strategy ETF","TMF":"3倍做多20年期以上国债ETF-Direxion","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","BK4585":"ETF&股票定投概念"},"translate_title":"欧元债券发售可能会改变投资Viatris(VTRS)的理由","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TMF":0.6,"FXE":1.5,"US30Y.BOND":1.5,"AIPO":0.61,"US3Y.BOND":1.5,"VTRS":1.5,"US10Y.BOND":1.5,"US5Y.BOND":1.5,"US12M.BOND":1.5,"TLTW":0.6,"TLT":0.6,"US6M.BOND":1.5,"US7Y.BOND":1.5,"US2Y.BOND":1.5},"content_text":"Viatris Inc. recently completed a euro-denominated fixed-income offering, issuing €648.30 million of 4.250% senior unsecured notes due June 17, 2033, at 99.739% of face value with attached guarantees and call features. This move adds euro currency debt to Viatris’ capital structure, raising questions about how the new funding mix may influence its balance sheet flexibility and future capital allocation. We’ll now examine how this new euro-denominated bond issuance, and the added euro debt on Viatris’ balance sheet, could reshape its investment narrative. AI is about to change healthcare. These 38 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.AdvertisementViatris Investment Narrative RecapTo own Viatris, you need to believe its global generics and emerging branded portfolio can convert modest revenue growth into sustainably higher cash generation, despite pricing and regulatory pressure. The new €648.30 million euro bond issue modestly shifts its funding mix, but does not appear to change the near term story, where the key catalyst is better profitability and the main risk remains pressure on off patent products and margins. The most relevant recent update alongside this bond sale is Viatris’ Q1 2026 earnings, which showed US$3,517.0 million in revenue and a return to net income of US$176.4 million after prior year losses. That improvement, together with reaffirmed full year 2026 revenue guidance of US$14.45 billion to US$14.95 billion, frames how investors might interpret the new euro debt: as another piece of a still evolving balance between funding, cost control and cautious capital returns. But against that backdrop, investors should also be aware of the risk that high leverage could still limit Viatris’ room to maneuver... Read the full narrative on Viatris (it's free!)Viatris' narrative projects $15.4 billion revenue and $954.5 million earnings by 2029. This requires 1.8% yearly revenue growth and a $1.25 billion earnings increase from -$296.5 million today.Uncover how Viatris' forecasts yield a $17.50 fair value, a 6% upside to its current price.Exploring Other PerspectivesVTRS 1-Year Stock Price Chart Some of the most optimistic analysts were expecting Viatris to reach about US$15.9 billion in revenue and roughly US$2.3 billion in earnings by 2029, so compared with the baseline concerns about pricing pressure and leverage, their narrative leans far more positive and the new euro debt could yet influence which of these very different outlooks feels more realistic to you.Explore 7 other fair value estimates on Viatris - why the stock might be worth over 3x more than the current price!Form Your Own VerdictDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your Viatris research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.Our free Viatris research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Viatris' overall financial health at a glance.Ready For A Different Approach?Our top stock finds are flying under the radar-for now. Get in early:Uncover the next big thing with 24 elite penny stocks that balance risk and reward.The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 14 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2643788173","isCrawlerRequest":true}